Evidence map›Paper›PMID 37765279›Full record

ArticlePharmaceutics2023

Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity.

Anife Ahmedova, Rositsa Mihaylova, Silviya Stoykova, Veronika Mihaylova, Nikola Burdzhiev, Viktoria Elincheva, Georgi Momekov, Denitsa Momekova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anife AhmedovaFaculty of Chemistry and Pharmacy, Sofia University, 1, J. Bourchier Blvd., 1164 Sofia, Bulgaria.ORCID 0000-0002-6288-648X
Rositsa MihaylovaFaculty of Pharmacy, Medical University-Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria.ORCID 0000-0001-5763-0730
Silviya StoykovaFaculty of Chemistry and Pharmacy, Sofia University, 1, J. Bourchier Blvd., 1164 Sofia, Bulgaria.
Veronika MihaylovaFaculty of Chemistry and Pharmacy, Sofia University, 1, J. Bourchier Blvd., 1164 Sofia, Bulgaria.
Nikola BurdzhievFaculty of Chemistry and Pharmacy, Sofia University, 1, J. Bourchier Blvd., 1164 Sofia, Bulgaria.ORCID 0000-0002-6785-7290
Viktoria ElinchevaFaculty of Pharmacy, Medical University-Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria.
Georgi MomekovFaculty of Pharmacy, Medical University-Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria.ORCID 0000-0003-2841-7089
Denitsa MomekovaFaculty of Pharmacy, Medical University-Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria.
Medical University of Sofia · BGSofia University "St. Kliment Ohridski" · BG

Funding

Bulgarian Science Fund КП-06-Н59/9
6 · The paper itself

Abstract

Research on platinum-based anticancer drugs continuously strives to develop new non-classical platinum complexes. Pt(IV) prodrugs are the most promising, and their activation-by-reduction mechanism of action is being explored as a prospect for higher selectivity and efficiency. Herein, we present the anticancer potency and chemical reactivity of Pt(IV) complexes formed by linking pyrene butyric acid with cisplatin. The results from cytotoxicity screening on 10 types of cancer cell lines and non-malignant cells (HEK-293) indicated IC

Indexed as

activation by reductionanticancer agentscellular uptakecytotoxicityplatinum(IV) prodrugs

Identifiers

PMID37765279
PMCPMC10537052
OpenAlexW4386715304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.